<a href="https://www.fiercebiotech.com/biotech/cardiovascular-focused-kardigan-plans-bring-cozy-320m-haul-upcoming-ipo" hreflang="en">Cardiovascular-focused Kardigan plans to bring in cozy $320M haul from upcoming IPO</a>
Kardigan, a Bay Area biotech focused on cardiovascular treatments, is set to raise $320 million through its upcoming IPO on Nasdaq, offering 23.3 million shares priced between $14 and $16 each. The funds will primarily support the development of its lead drug, danicamtiv, and other assets targeting various heart conditions.
Kardigan's upcoming IPO, aiming to raise $320 million, highlights a strategic focus on advancing its innovative cardiovascular pipeline with assets like danicamtiv and ataciguat. For a professional tracking biotech IPOs and cardiovascular advancements, this presents a notable investment signal, especially given Kardigan's leadership team with a proven track record from MyoKardia and the potential of their lead compounds in addressing significant unmet needs in genetic dilated cardiomyopathy and calcific aortic valve stenosis.